 Jeremy Prager
Concepts (421)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Trachea | 13 | 2022 | 249 | 2.830 |
Why?
| | Tonsillectomy | 5 | 2025 | 94 | 2.280 |
Why?
| | Otolaryngology | 7 | 2022 | 93 | 1.920 |
Why?
| | Laryngoscopy | 8 | 2024 | 106 | 1.660 |
Why?
| | Tracheal Stenosis | 6 | 2023 | 31 | 1.580 |
Why?
| | Respiratory Tract Diseases | 4 | 2019 | 180 | 1.570 |
Why?
| | Bronchoscopy | 12 | 2021 | 218 | 1.400 |
Why?
| | Larynx | 4 | 2024 | 60 | 1.250 |
Why?
| | Tracheomalacia | 4 | 2022 | 17 | 1.190 |
Why?
| | Correspondence as Topic | 3 | 2012 | 16 | 1.100 |
Why?
| | Postoperative Nausea and Vomiting | 1 | 2025 | 18 | 0.950 |
Why?
| | Deglutition Disorders | 4 | 2023 | 148 | 0.950 |
Why?
| | Laryngostenosis | 3 | 2023 | 50 | 0.950 |
Why?
| | Papilloma | 1 | 2025 | 51 | 0.930 |
Why?
| | Respiratory Distress Syndrome, Newborn | 2 | 2018 | 104 | 0.930 |
Why?
| | Otitis Media | 7 | 2023 | 167 | 0.920 |
Why?
| | Antiemetics | 1 | 2025 | 45 | 0.920 |
Why?
| | Oropharyngeal Neoplasms | 1 | 2025 | 53 | 0.900 |
Why?
| | Mouth Neoplasms | 1 | 2025 | 86 | 0.890 |
Why?
| | Child | 54 | 2025 | 21833 | 0.860 |
Why?
| | Airway Obstruction | 6 | 2021 | 156 | 0.850 |
Why?
| | Esophagoscopy | 4 | 2020 | 210 | 0.820 |
Why?
| | Efficiency, Organizational | 4 | 2019 | 139 | 0.800 |
Why?
| | Dexamethasone | 1 | 2025 | 365 | 0.800 |
Why?
| | Papillomavirus Infections | 3 | 2025 | 378 | 0.800 |
Why?
| | Operating Rooms | 2 | 2015 | 124 | 0.790 |
Why?
| | Gastrointestinal Diseases | 3 | 2019 | 208 | 0.770 |
Why?
| | Otorhinolaryngologic Surgical Procedures | 3 | 2021 | 38 | 0.740 |
Why?
| | Adenoidectomy | 4 | 2021 | 72 | 0.730 |
Why?
| | Otorhinolaryngologic Diseases | 2 | 2019 | 16 | 0.710 |
Why?
| | Polytetrafluoroethylene | 1 | 2021 | 23 | 0.710 |
Why?
| | Respiratory Sounds | 2 | 2018 | 109 | 0.690 |
Why?
| | Abscess | 1 | 2020 | 75 | 0.650 |
Why?
| | Congenital Abnormalities | 2 | 2024 | 92 | 0.630 |
Why?
| | Ancillary Services, Hospital | 1 | 2019 | 2 | 0.630 |
Why?
| | Child, Preschool | 32 | 2025 | 11102 | 0.630 |
Why?
| | Hospitals, Pediatric | 6 | 2020 | 516 | 0.620 |
Why?
| | Hematologic Neoplasms | 1 | 2021 | 157 | 0.620 |
Why?
| | Digestive System Diseases | 1 | 2019 | 26 | 0.610 |
Why?
| | Internship and Residency | 4 | 2020 | 1172 | 0.600 |
Why?
| | Patient Care Team | 3 | 2019 | 634 | 0.600 |
Why?
| | Helicobacter Infections | 1 | 2018 | 30 | 0.590 |
Why?
| | Helicobacter pylori | 1 | 2018 | 42 | 0.590 |
Why?
| | Craniocerebral Trauma | 1 | 2020 | 168 | 0.580 |
Why?
| | Humans | 84 | 2025 | 137601 | 0.570 |
Why?
| | Tracheal Neoplasms | 1 | 2018 | 9 | 0.570 |
Why?
| | Intubation, Intratracheal | 3 | 2015 | 259 | 0.570 |
Why?
| | Tracheostomy | 2 | 2019 | 129 | 0.560 |
Why?
| | Eosinophilic Esophagitis | 3 | 2019 | 325 | 0.550 |
Why?
| | Paraganglioma | 1 | 2018 | 52 | 0.520 |
Why?
| | Quality Improvement | 3 | 2016 | 1180 | 0.500 |
Why?
| | Male | 47 | 2025 | 67690 | 0.490 |
Why?
| | Retrospective Studies | 24 | 2025 | 15720 | 0.480 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2019 | 276 | 0.480 |
Why?
| | Gastroesophageal Reflux | 4 | 2023 | 239 | 0.480 |
Why?
| | Tracheoesophageal Fistula | 3 | 2022 | 33 | 0.470 |
Why?
| | Natural Orifice Endoscopic Surgery | 1 | 2015 | 34 | 0.460 |
Why?
| | Clinical Competence | 4 | 2020 | 1122 | 0.460 |
Why?
| | Patient Satisfaction | 2 | 2019 | 677 | 0.460 |
Why?
| | Spinal Fractures | 1 | 2015 | 74 | 0.460 |
Why?
| | Gastroenterology | 3 | 2023 | 178 | 0.450 |
Why?
| | Infant | 22 | 2024 | 9539 | 0.450 |
Why?
| | Phenol | 1 | 2014 | 19 | 0.440 |
Why?
| | Drug Labeling | 1 | 2014 | 38 | 0.440 |
Why?
| | Delphi Technique | 8 | 2024 | 278 | 0.430 |
Why?
| | Anti-Infective Agents, Local | 1 | 2014 | 41 | 0.430 |
Why?
| | Burns, Chemical | 1 | 2014 | 33 | 0.430 |
Why?
| | Postoperative Complications | 6 | 2022 | 2665 | 0.420 |
Why?
| | Medical Audit | 1 | 2014 | 76 | 0.420 |
Why?
| | Female | 43 | 2025 | 73359 | 0.410 |
Why?
| | Chromosome Disorders | 1 | 2013 | 43 | 0.410 |
Why?
| | Consensus | 7 | 2024 | 673 | 0.410 |
Why?
| | Thyroid Neoplasms | 3 | 2023 | 324 | 0.390 |
Why?
| | Career Choice | 2 | 2011 | 227 | 0.390 |
Why?
| | Wounds, Nonpenetrating | 1 | 2015 | 286 | 0.380 |
Why?
| | Sleep Apnea Syndromes | 1 | 2013 | 89 | 0.370 |
Why?
| | Abnormalities, Multiple | 1 | 2013 | 195 | 0.370 |
Why?
| | Student Dropouts | 1 | 2011 | 8 | 0.360 |
Why?
| | Adolescent | 25 | 2025 | 21435 | 0.360 |
Why?
| | Writing | 1 | 2012 | 99 | 0.350 |
Why?
| | Job Description | 1 | 2010 | 14 | 0.340 |
Why?
| | Minimally Invasive Surgical Procedures | 1 | 2012 | 174 | 0.340 |
Why?
| | Deafness | 1 | 2012 | 77 | 0.340 |
Why?
| | Cochlear Implantation | 1 | 2012 | 75 | 0.340 |
Why?
| | Pharyngeal Diseases | 1 | 2010 | 16 | 0.340 |
Why?
| | Endoscopy, Gastrointestinal | 2 | 2024 | 229 | 0.340 |
Why?
| | Education, Medical, Continuing | 1 | 2011 | 128 | 0.340 |
Why?
| | Pediatrics | 4 | 2019 | 1071 | 0.340 |
Why?
| | School Admission Criteria | 1 | 2010 | 29 | 0.330 |
Why?
| | Bronchiectasis | 3 | 2020 | 110 | 0.330 |
Why?
| | Pain, Postoperative | 2 | 2025 | 281 | 0.330 |
Why?
| | Pulmonary Embolism | 1 | 2013 | 233 | 0.330 |
Why?
| | Fucosyltransferases | 2 | 2022 | 33 | 0.330 |
Why?
| | Intestinal Mucosa | 1 | 2015 | 620 | 0.320 |
Why?
| | Personnel Selection | 1 | 2010 | 81 | 0.310 |
Why?
| | Tracheotomy | 4 | 2019 | 24 | 0.310 |
Why?
| | Palatine Tonsil | 2 | 2021 | 53 | 0.290 |
Why?
| | Thoracoscopy | 2 | 2019 | 54 | 0.290 |
Why?
| | Microbiota | 5 | 2023 | 759 | 0.290 |
Why?
| | Infant, Newborn | 8 | 2023 | 6125 | 0.290 |
Why?
| | Esophageal Atresia | 2 | 2020 | 26 | 0.290 |
Why?
| | Anesthesia | 2 | 2023 | 192 | 0.280 |
Why?
| | Hearing Loss, Conductive | 1 | 2007 | 24 | 0.280 |
Why?
| | Faculty, Medical | 1 | 2010 | 288 | 0.270 |
Why?
| | Craniosynostoses | 1 | 2007 | 57 | 0.260 |
Why?
| | Ear, Middle | 5 | 2023 | 84 | 0.250 |
Why?
| | Program Development | 2 | 2019 | 362 | 0.250 |
Why?
| | Treatment Outcome | 9 | 2024 | 10813 | 0.250 |
Why?
| | Deglutition | 2 | 2024 | 71 | 0.250 |
Why?
| | Surgeons | 2 | 2020 | 306 | 0.240 |
Why?
| | Down Syndrome | 2 | 2023 | 486 | 0.240 |
Why?
| | Practice Guidelines as Topic | 2 | 2018 | 1541 | 0.230 |
Why?
| | Tracheobronchomalacia | 2 | 2022 | 15 | 0.230 |
Why?
| | Biopsy | 3 | 2019 | 1089 | 0.230 |
Why?
| | Administration, Intravenous | 1 | 2025 | 154 | 0.230 |
Why?
| | Respiratory Tract Infections | 3 | 2021 | 384 | 0.220 |
Why?
| | Nasal Septal Perforation | 1 | 2024 | 4 | 0.220 |
Why?
| | Fascia | 1 | 2024 | 17 | 0.220 |
Why?
| | Papillomaviridae | 1 | 2025 | 133 | 0.220 |
Why?
| | Sutures | 2 | 2021 | 59 | 0.220 |
Why?
| | Multiple Endocrine Neoplasia | 1 | 2023 | 5 | 0.210 |
Why?
| | Multiple Endocrine Neoplasia Type 2b | 1 | 2023 | 6 | 0.210 |
Why?
| | Multiple Endocrine Neoplasia Type 2a | 1 | 2023 | 14 | 0.210 |
Why?
| | Membrane Proteins | 2 | 2021 | 1152 | 0.200 |
Why?
| | Croup | 1 | 2023 | 19 | 0.200 |
Why?
| | Administration, Oral | 1 | 2025 | 785 | 0.200 |
Why?
| | Prospective Studies | 5 | 2025 | 7580 | 0.200 |
Why?
| | Vocal Cord Dysfunction | 1 | 2022 | 9 | 0.190 |
Why?
| | Hypoparathyroidism | 1 | 2022 | 5 | 0.190 |
Why?
| | Recurrent Laryngeal Nerve Injuries | 1 | 2022 | 12 | 0.190 |
Why?
| | Laryngoscopes | 1 | 2022 | 36 | 0.180 |
Why?
| | Colorado | 5 | 2020 | 4515 | 0.180 |
Why?
| | Graves Disease | 1 | 2022 | 34 | 0.180 |
Why?
| | Constriction, Pathologic | 4 | 2023 | 238 | 0.180 |
Why?
| | Cadherin Related Proteins | 1 | 2021 | 13 | 0.180 |
Why?
| | Nasopharynx | 1 | 2022 | 72 | 0.180 |
Why?
| | Haemophilus Infections | 1 | 2022 | 41 | 0.180 |
Why?
| | Medicine | 1 | 2023 | 126 | 0.180 |
Why?
| | Acrocephalosyndactylia | 1 | 2021 | 12 | 0.170 |
Why?
| | Job Satisfaction | 1 | 2023 | 215 | 0.170 |
Why?
| | Nasal Obstruction | 1 | 2021 | 27 | 0.170 |
Why?
| | Double-Blind Method | 1 | 2025 | 1921 | 0.170 |
Why?
| | Nasal Septum | 1 | 2020 | 25 | 0.170 |
Why?
| | Plasminogen | 1 | 2020 | 30 | 0.170 |
Why?
| | Hematoma | 1 | 2020 | 54 | 0.170 |
Why?
| | Mucolipidoses | 1 | 2020 | 8 | 0.160 |
Why?
| | Bevacizumab | 1 | 2021 | 138 | 0.160 |
Why?
| | Follow-Up Studies | 7 | 2019 | 5121 | 0.160 |
Why?
| | Bone Marrow Transplantation | 4 | 1997 | 288 | 0.160 |
Why?
| | Respiratory Tract Fistula | 1 | 2019 | 7 | 0.160 |
Why?
| | Cutaneous Fistula | 1 | 2019 | 14 | 0.160 |
Why?
| | Tracheal Diseases | 1 | 2019 | 16 | 0.160 |
Why?
| | Cartilage | 1 | 2021 | 192 | 0.150 |
Why?
| | Arytenoid Cartilage | 1 | 2019 | 7 | 0.150 |
Why?
| | alpha-Macroglobulins | 1 | 2019 | 24 | 0.150 |
Why?
| | Speech-Language Pathology | 1 | 2019 | 23 | 0.150 |
Why?
| | Angiogenesis Inhibitors | 1 | 2021 | 230 | 0.150 |
Why?
| | Laryngomalacia | 1 | 2018 | 5 | 0.150 |
Why?
| | Chemoreceptor Cells | 1 | 2019 | 52 | 0.150 |
Why?
| | Laryngoplasty | 1 | 2018 | 6 | 0.150 |
Why?
| | Registries | 2 | 2024 | 2043 | 0.150 |
Why?
| | Young Adult | 9 | 2024 | 13203 | 0.150 |
Why?
| | Models, Organizational | 1 | 2019 | 149 | 0.150 |
Why?
| | Mutation, Missense | 1 | 2020 | 340 | 0.150 |
Why?
| | Airway Extubation | 1 | 2019 | 59 | 0.150 |
Why?
| | Pulmonary Medicine | 1 | 2019 | 81 | 0.140 |
Why?
| | Interdisciplinary Communication | 1 | 2019 | 185 | 0.140 |
Why?
| | United States | 7 | 2019 | 14925 | 0.140 |
Why?
| | Respiratory System | 1 | 2019 | 155 | 0.140 |
Why?
| | Vascular Diseases | 1 | 2020 | 240 | 0.140 |
Why?
| | Respiration Disorders | 1 | 2018 | 78 | 0.140 |
Why?
| | Esophageal Mucosa | 1 | 2018 | 22 | 0.140 |
Why?
| | Child Behavior | 1 | 2020 | 245 | 0.140 |
Why?
| | Severity of Illness Index | 4 | 2016 | 2840 | 0.140 |
Why?
| | Proton Pump Inhibitors | 1 | 2018 | 109 | 0.140 |
Why?
| | Virtual Reality | 1 | 2019 | 65 | 0.140 |
Why?
| | Carcinoma, Medullary | 1 | 2017 | 17 | 0.130 |
Why?
| | Betacoronavirus | 1 | 2020 | 270 | 0.130 |
Why?
| | Bronchopulmonary Dysplasia | 1 | 2022 | 387 | 0.130 |
Why?
| | Reoperation | 2 | 2018 | 579 | 0.130 |
Why?
| | Down-Regulation | 1 | 2019 | 635 | 0.130 |
Why?
| | Burnout, Professional | 1 | 2023 | 442 | 0.130 |
Why?
| | Cost-Benefit Analysis | 1 | 2019 | 592 | 0.130 |
Why?
| | Gastrostomy | 1 | 2018 | 117 | 0.130 |
Why?
| | Sequence Analysis, DNA | 1 | 2019 | 826 | 0.120 |
Why?
| | Neuromuscular Nondepolarizing Agents | 1 | 2015 | 15 | 0.120 |
Why?
| | Androstanols | 1 | 2015 | 17 | 0.120 |
Why?
| | Genetic Predisposition to Disease | 3 | 2021 | 2365 | 0.120 |
Why?
| | Anesthetics, Intravenous | 1 | 2015 | 48 | 0.120 |
Why?
| | RNA, Ribosomal, 16S | 3 | 2023 | 553 | 0.120 |
Why?
| | Midazolam | 1 | 2015 | 58 | 0.120 |
Why?
| | Clinical Audit | 1 | 2015 | 14 | 0.120 |
Why?
| | Time and Motion Studies | 1 | 2015 | 25 | 0.110 |
Why?
| | Mouth | 1 | 2015 | 87 | 0.110 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 369 | 0.110 |
Why?
| | Surveys and Questionnaires | 5 | 2024 | 5835 | 0.110 |
Why?
| | Esophagus | 3 | 2024 | 255 | 0.110 |
Why?
| | Coronavirus Infections | 1 | 2020 | 367 | 0.110 |
Why?
| | Reproducibility of Results | 3 | 2024 | 3287 | 0.110 |
Why?
| | DNA, Recombinant | 1 | 2014 | 48 | 0.110 |
Why?
| | Fentanyl | 1 | 2015 | 100 | 0.110 |
Why?
| | Program Evaluation | 1 | 2019 | 909 | 0.110 |
Why?
| | Prognosis | 3 | 2018 | 3966 | 0.110 |
Why?
| | Respiratory Aspiration | 1 | 2014 | 31 | 0.110 |
Why?
| | Survival Rate | 2 | 2018 | 1906 | 0.110 |
Why?
| | Tomography, X-Ray Computed | 3 | 2020 | 2679 | 0.110 |
Why?
| | Administration, Intranasal | 1 | 2014 | 89 | 0.110 |
Why?
| | Pedigree | 3 | 2020 | 511 | 0.110 |
Why?
| | Bronchogenic Cyst | 1 | 2013 | 7 | 0.110 |
Why?
| | Quality of Health Care | 1 | 2019 | 649 | 0.110 |
Why?
| | Iatrogenic Disease | 1 | 2014 | 67 | 0.110 |
Why?
| | Anesthetics, Local | 1 | 2014 | 82 | 0.110 |
Why?
| | Chromosomes, Human, Pair 1 | 1 | 2013 | 71 | 0.100 |
Why?
| | Patient Outcome Assessment | 1 | 2014 | 130 | 0.100 |
Why?
| | Chromosome Deletion | 1 | 2013 | 114 | 0.100 |
Why?
| | Appointments and Schedules | 1 | 2014 | 92 | 0.100 |
Why?
| | Genetic Variation | 1 | 2018 | 1001 | 0.100 |
Why?
| | Ambulatory Care | 1 | 2018 | 571 | 0.100 |
Why?
| | Radiography | 1 | 2015 | 844 | 0.100 |
Why?
| | Pharyngitis | 1 | 2013 | 24 | 0.100 |
Why?
| | Rhinitis | 1 | 2014 | 156 | 0.100 |
Why?
| | Neuralgia | 1 | 2014 | 134 | 0.100 |
Why?
| | Tetanus Antitoxin | 1 | 1992 | 3 | 0.100 |
Why?
| | Tetanus Toxoid | 1 | 1992 | 37 | 0.100 |
Why?
| | Antibodies | 1 | 2014 | 406 | 0.090 |
Why?
| | Fatal Outcome | 1 | 2013 | 309 | 0.090 |
Why?
| | Graft Rejection | 1 | 2016 | 577 | 0.090 |
Why?
| | Gene Expression Profiling | 1 | 2019 | 1752 | 0.090 |
Why?
| | Immunization, Secondary | 1 | 1992 | 87 | 0.090 |
Why?
| | Sinusitis | 1 | 2014 | 221 | 0.090 |
Why?
| | Academic Medical Centers | 1 | 2015 | 506 | 0.090 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2014 | 551 | 0.090 |
Why?
| | Mutation | 2 | 2021 | 3991 | 0.090 |
Why?
| | Pandemics | 1 | 2020 | 1627 | 0.090 |
Why?
| | Patient Safety | 1 | 2015 | 320 | 0.090 |
Why?
| | Cytosine | 1 | 2011 | 48 | 0.090 |
Why?
| | Time Factors | 3 | 2019 | 6818 | 0.090 |
Why?
| | Asthma | 1 | 2023 | 1886 | 0.080 |
Why?
| | Off-Label Use | 1 | 2011 | 53 | 0.080 |
Why?
| | Ear Ossicles | 1 | 2010 | 11 | 0.080 |
Why?
| | Patient Readmission | 1 | 2016 | 701 | 0.080 |
Why?
| | Airway Management | 1 | 2011 | 52 | 0.080 |
Why?
| | Organophosphonates | 1 | 2011 | 99 | 0.080 |
Why?
| | Endoscopy, Digestive System | 2 | 2024 | 135 | 0.080 |
Why?
| | Professional Competence | 1 | 2010 | 97 | 0.080 |
Why?
| | Referral and Consultation | 1 | 2015 | 794 | 0.080 |
Why?
| | Disclosure | 1 | 2010 | 112 | 0.080 |
Why?
| | Teratoma | 1 | 2011 | 118 | 0.080 |
Why?
| | Thyroidectomy | 2 | 2022 | 95 | 0.080 |
Why?
| | Patient Selection | 1 | 2012 | 687 | 0.070 |
Why?
| | Hospitalization | 1 | 2018 | 2197 | 0.070 |
Why?
| | Communication | 1 | 2015 | 922 | 0.070 |
Why?
| | Electronic Health Records | 1 | 2016 | 1073 | 0.070 |
Why?
| | Magnetic Resonance Imaging | 2 | 2018 | 3607 | 0.070 |
Why?
| | Mice | 6 | 2022 | 17748 | 0.070 |
Why?
| | Middle Ear Ventilation | 1 | 2007 | 15 | 0.070 |
Why?
| | Audiometry | 1 | 2007 | 27 | 0.070 |
Why?
| | Prevalence | 2 | 2020 | 2735 | 0.070 |
Why?
| | RNA, Messenger | 1 | 2014 | 2798 | 0.060 |
Why?
| | Risk Factors | 3 | 2019 | 10319 | 0.060 |
Why?
| | Antiviral Agents | 2 | 2011 | 760 | 0.060 |
Why?
| | Hematologic Diseases | 1 | 1986 | 64 | 0.060 |
Why?
| | Catheters, Indwelling | 1 | 1986 | 89 | 0.060 |
Why?
| | Head and Neck Neoplasms | 1 | 2011 | 553 | 0.060 |
Why?
| | Pilot Projects | 1 | 2010 | 1742 | 0.060 |
Why?
| | Practice Patterns, Physicians' | 1 | 2014 | 1299 | 0.060 |
Why?
| | Temporal Muscle | 1 | 2024 | 3 | 0.060 |
Why?
| | Cadaver | 2 | 2019 | 293 | 0.060 |
Why?
| | Absorbable Implants | 1 | 2024 | 36 | 0.050 |
Why?
| | Polyesters | 1 | 2024 | 77 | 0.050 |
Why?
| | Video Recording | 1 | 2024 | 176 | 0.050 |
Why?
| | Transplantation, Homologous | 4 | 2011 | 412 | 0.050 |
Why?
| | Observer Variation | 1 | 2024 | 349 | 0.050 |
Why?
| | Carcinoma, Neuroendocrine | 1 | 2023 | 34 | 0.050 |
Why?
| | Animals | 6 | 2022 | 37088 | 0.050 |
Why?
| | Hyperplasia | 1 | 2023 | 176 | 0.050 |
Why?
| | Breathing Exercises | 1 | 2022 | 20 | 0.050 |
Why?
| | Vocal Cords | 1 | 2022 | 32 | 0.050 |
Why?
| | Cough | 1 | 2023 | 125 | 0.050 |
Why?
| | Biofeedback, Psychology | 1 | 2022 | 36 | 0.050 |
Why?
| | Haemophilus influenzae | 1 | 2022 | 63 | 0.040 |
Why?
| | Bayes Theorem | 1 | 2023 | 410 | 0.040 |
Why?
| | Leukemia, Myeloid, Acute | 3 | 1992 | 632 | 0.040 |
Why?
| | Esophagoscopes | 1 | 2020 | 5 | 0.040 |
Why?
| | Nasal Cavity | 1 | 2021 | 54 | 0.040 |
Why?
| | Perioperative Period | 1 | 2020 | 56 | 0.040 |
Why?
| | Internationality | 1 | 2021 | 158 | 0.040 |
Why?
| | Adrenal Cortex Hormones | 1 | 2023 | 491 | 0.040 |
Why?
| | Antineoplastic Agents | 1 | 2011 | 2128 | 0.040 |
Why?
| | Philippines | 1 | 2019 | 50 | 0.040 |
Why?
| | Laryngeal Mucosa | 1 | 2019 | 8 | 0.040 |
Why?
| | Foreign Bodies | 1 | 2020 | 105 | 0.040 |
Why?
| | Pakistan | 1 | 2019 | 76 | 0.040 |
Why?
| | Finland | 1 | 2019 | 78 | 0.040 |
Why?
| | Mice, Inbred C57BL | 2 | 2021 | 5764 | 0.040 |
Why?
| | Single-Blind Method | 1 | 2019 | 283 | 0.040 |
Why?
| | Lung | 2 | 2023 | 4057 | 0.040 |
Why?
| | Saliva | 1 | 2020 | 238 | 0.040 |
Why?
| | Social Support | 1 | 2023 | 628 | 0.040 |
Why?
| | Esophageal pH Monitoring | 1 | 2018 | 23 | 0.040 |
Why?
| | California | 1 | 2020 | 440 | 0.040 |
Why?
| | Nerve Fibers | 1 | 2019 | 97 | 0.040 |
Why?
| | Clinical Protocols | 1 | 2020 | 268 | 0.040 |
Why?
| | Patient Reported Outcome Measures | 1 | 2022 | 403 | 0.040 |
Why?
| | COS Cells | 1 | 2018 | 183 | 0.040 |
Why?
| | Electric Impedance | 1 | 2018 | 109 | 0.040 |
Why?
| | Device Removal | 1 | 2019 | 135 | 0.040 |
Why?
| | Interdisciplinary Research | 1 | 2018 | 26 | 0.030 |
Why?
| | Emotions | 1 | 2023 | 561 | 0.030 |
Why?
| | Infant, Premature | 1 | 2022 | 579 | 0.030 |
Why?
| | Anesthetics | 1 | 2018 | 81 | 0.030 |
Why?
| | Exome | 1 | 2018 | 234 | 0.030 |
Why?
| | Chickenpox Vaccine | 1 | 1997 | 74 | 0.030 |
Why?
| | Transplantation, Autologous | 3 | 1992 | 242 | 0.030 |
Why?
| | Ultrasonography, Doppler | 1 | 2017 | 123 | 0.030 |
Why?
| | Sequence Analysis, RNA | 1 | 2019 | 451 | 0.030 |
Why?
| | Ambulatory Care Facilities | 1 | 2018 | 243 | 0.030 |
Why?
| | Taste Buds | 1 | 2019 | 203 | 0.030 |
Why?
| | Perioperative Care | 1 | 2018 | 180 | 0.030 |
Why?
| | Survival Analysis | 2 | 2017 | 1289 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2018 | 730 | 0.030 |
Why?
| | Terminology as Topic | 1 | 2018 | 245 | 0.030 |
Why?
| | Recurrence | 1 | 2019 | 1073 | 0.030 |
Why?
| | Patient-Centered Care | 1 | 2021 | 540 | 0.030 |
Why?
| | Comorbidity | 1 | 2020 | 1634 | 0.030 |
Why?
| | Neoplasm Invasiveness | 1 | 2017 | 498 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2017 | 672 | 0.030 |
Why?
| | Age Factors | 2 | 2014 | 3253 | 0.030 |
Why?
| | Tongue | 1 | 2015 | 82 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2019 | 964 | 0.030 |
Why?
| | Health Services Research | 1 | 2018 | 403 | 0.030 |
Why?
| | Hypertrophy | 1 | 2015 | 132 | 0.030 |
Why?
| | Genomics | 1 | 2020 | 803 | 0.030 |
Why?
| | Transcriptome | 1 | 2021 | 969 | 0.030 |
Why?
| | Long-Term Care | 1 | 2015 | 106 | 0.030 |
Why?
| | Adolescent Behavior | 1 | 2020 | 530 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2019 | 1718 | 0.030 |
Why?
| | Disease Management | 1 | 2019 | 619 | 0.030 |
Why?
| | Benzofurans | 1 | 2014 | 21 | 0.030 |
Why?
| | Pain Threshold | 1 | 2014 | 74 | 0.030 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2020 | 624 | 0.030 |
Why?
| | Neural Conduction | 1 | 2014 | 89 | 0.030 |
Why?
| | TRPV Cation Channels | 1 | 2014 | 41 | 0.030 |
Why?
| | Ganglia, Spinal | 1 | 2014 | 78 | 0.030 |
Why?
| | Sensory Receptor Cells | 1 | 2014 | 96 | 0.030 |
Why?
| | Hyperalgesia | 1 | 2014 | 123 | 0.030 |
Why?
| | Thoracotomy | 1 | 2013 | 76 | 0.030 |
Why?
| | Quinolines | 1 | 2014 | 153 | 0.030 |
Why?
| | Neoplasm Staging | 1 | 2017 | 1359 | 0.030 |
Why?
| | Fetal Therapies | 1 | 2013 | 42 | 0.030 |
Why?
| | Rats, Wistar | 1 | 2014 | 448 | 0.020 |
Why?
| | Cell Line | 1 | 2018 | 2864 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2020 | 2143 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2020 | 2836 | 0.020 |
Why?
| | Adult | 5 | 2023 | 37910 | 0.020 |
Why?
| | Early Detection of Cancer | 1 | 2017 | 432 | 0.020 |
Why?
| | Tetanus | 1 | 1992 | 26 | 0.020 |
Why?
| | Anemia, Aplastic | 1 | 1992 | 42 | 0.020 |
Why?
| | Pain Measurement | 1 | 2014 | 527 | 0.020 |
Why?
| | Endoscopy | 1 | 2014 | 313 | 0.020 |
Why?
| | Ultrasonography, Prenatal | 1 | 2013 | 285 | 0.020 |
Why?
| | Cohort Studies | 1 | 2022 | 5691 | 0.020 |
Why?
| | Injections, Intralesional | 1 | 2011 | 35 | 0.020 |
Why?
| | Neoplasms | 1 | 1986 | 2691 | 0.020 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2015 | 302 | 0.020 |
Why?
| | Enzyme Inhibitors | 1 | 2014 | 847 | 0.020 |
Why?
| | Malleus | 1 | 2010 | 1 | 0.020 |
Why?
| | Incus | 1 | 2010 | 6 | 0.020 |
Why?
| | Incidence | 1 | 2017 | 2805 | 0.020 |
Why?
| | Stapes | 1 | 2010 | 25 | 0.020 |
Why?
| | Temporal Bone | 1 | 2010 | 42 | 0.020 |
Why?
| | Inflammation | 1 | 2021 | 2841 | 0.020 |
Why?
| | Graft vs Host Disease | 1 | 1992 | 252 | 0.020 |
Why?
| | Aerosols | 1 | 2011 | 178 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2019 | 2583 | 0.020 |
Why?
| | Administration, Inhalation | 1 | 2011 | 590 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2014 | 2165 | 0.020 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 1992 | 290 | 0.020 |
Why?
| | Graft Survival | 1 | 2011 | 527 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 2010 | 1088 | 0.020 |
Why?
| | Chronic Disease | 1 | 2014 | 1788 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2011 | 1488 | 0.020 |
Why?
| | Stents | 1 | 2011 | 523 | 0.020 |
Why?
| | Imaging, Three-Dimensional | 1 | 2010 | 564 | 0.020 |
Why?
| | Ultrasonography | 1 | 2010 | 762 | 0.020 |
Why?
| | Logistic Models | 1 | 2011 | 2076 | 0.020 |
Why?
| | Rats | 1 | 2014 | 5558 | 0.010 |
Why?
| | Signal Transduction | 1 | 2019 | 5060 | 0.010 |
Why?
| | Heart Atria | 1 | 1986 | 134 | 0.010 |
Why?
| | Anti-Bacterial Agents | 1 | 2014 | 1799 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2015 | 5507 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2014 | 4301 | 0.010 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 1991 | 1706 | 0.010 |
Why?
| | Pancreatic Function Tests | 1 | 1981 | 3 | 0.010 |
Why?
| | Exocrine Pancreatic Insufficiency | 1 | 1981 | 22 | 0.010 |
Why?
| | Pregnancy | 1 | 2013 | 6770 | 0.010 |
Why?
| | Somatostatin | 1 | 1980 | 58 | 0.010 |
Why?
| | Middle Aged | 3 | 2019 | 33441 | 0.010 |
Why?
| | Dietary Fats | 1 | 1980 | 303 | 0.010 |
Why?
| | Bromodeoxyuridine | 1 | 1997 | 78 | 0.010 |
Why?
| | Triglycerides | 1 | 1980 | 515 | 0.010 |
Why?
| | Chickenpox | 1 | 1997 | 81 | 0.010 |
Why?
| | Immune Tolerance | 1 | 1997 | 366 | 0.010 |
Why?
| | Herpes Zoster | 1 | 1997 | 314 | 0.010 |
Why?
| | Antibodies, Viral | 1 | 1997 | 648 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 1997 | 2022 | 0.010 |
Why?
| | Immunoglobulin G | 1 | 1997 | 902 | 0.010 |
Why?
| | Bone Marrow Purging | 1 | 1991 | 3 | 0.010 |
Why?
| | Daunorubicin | 1 | 1991 | 24 | 0.010 |
Why?
| | Thioguanine | 1 | 1991 | 19 | 0.010 |
Why?
| | Cytarabine | 1 | 1991 | 60 | 0.010 |
Why?
| | Leukocyte Count | 1 | 1992 | 320 | 0.010 |
Why?
| | Remission Induction | 1 | 1992 | 290 | 0.010 |
Why?
| | Combined Modality Therapy | 1 | 1991 | 1226 | 0.000 |
Why?
| | Vaccination | 1 | 1997 | 1430 | 0.000 |
Why?
| | Fluoresceins | 1 | 1981 | 49 | 0.000 |
Why?
| | Lipase | 1 | 1980 | 69 | 0.000 |
Why?
| | Fatty Acids, Nonesterified | 1 | 1980 | 158 | 0.000 |
Why?
| | Cholesterol | 1 | 1980 | 400 | 0.000 |
Why?
| | Blood Glucose | 1 | 1980 | 2188 | 0.000 |
Why?
| | Insulin | 1 | 1980 | 2404 | 0.000 |
Why?
|
|
Prager's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|